These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8822053)

  • 1. [In vitro antibacterial activity of pazufloxacin (PZFX) against clinical isolates from infectious enteritis].
    Fukuyama M; Oonaka K; Hara M; Imagawa Y
    Kansenshogaku Zasshi; 1996 Jan; 70(1):51-9. PubMed ID: 8822053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Basic and clinical studies of pazufloxacin on infectious enteritis research group of T-3761 on infectious enteritis].
    Sagara H; Yoshikawa K; Tomizawa I; Takizawa Y; Nitta Y; Tsunoda T; Fukuda H; Yamaguchi T; Masuda G; Negishi M; Ajisawa A; Murata M; Ohnishi K; Irimajiri S; Obana M; Matsumoto F; Imai T; Sakurai I; Takahashi T; Mori M; Mizuno Y; Katoh K; Hosoda S; Bamba T; Saito M
    Kansenshogaku Zasshi; 1996 Jan; 70(1):60-72. PubMed ID: 8822054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro antibacterial activity of fleroxacin (FLRX) against clinical isolates from bacterial enteritis].
    Imagawa Y; Fukuyama M; Kawakami K; Suda O
    Kansenshogaku Zasshi; 1994 Nov; 68(11):1409-16. PubMed ID: 7829909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro antibacterial activity of balofloxacin (BLFX) against isolates from patients with bacterial enteritis].
    Fukuyama M; Kawakami K; Suda O; Imagawa Y
    Kansenshogaku Zasshi; 1995 Sep; 69(9):987-90. PubMed ID: 7594800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study of prulifloxacin on infectious enteritis. Japan Research Committee of Prulifloxacin, Research Group on Infectious Enteritis].
    Tomizawa I; Takizawa Y; Nitta Y; Tsunoda T; Fukuda H; Yamaguchi T; Masuda G; Negishi M; Ajisawa A; Murata M; Ohnishi K; Irimajiri S; Obana M; Sajima Y; Sagara H; Kato H; Hosoda S; Banba T; Sasaki M; Yoshikawa K; Nakagawa M; Ohkubo H; Kim Y; Akao M; Fukuyama M
    Kansenshogaku Zasshi; 1996 Jul; 70(7):727-45. PubMed ID: 8797308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro antimicrobial activity of DR-3355, a new quinolone antibacterial agent, against clinical isolates of enteritis-causing bacteria].
    Horiuchi S; Inagaki Y; Yamamoto N; Ogawa M; Nakaya R
    Kansenshogaku Zasshi; 1992 Jan; 66(1):51-8. PubMed ID: 1402063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phototoxicity studies of pazufloxacin mesilate, a novel parenteral quinolone antimicrobial agent--in vitro and in vivo studies].
    Nagasawa M; Nakamura S; Miyazaki M; Nojima Y; Hayakawa H; Kawamura Y
    Jpn J Antibiot; 2002 Jun; 55(3):259-69. PubMed ID: 12199110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antibacterial activity of fosfomycin against the causative bacteria isolated from bacterial enteritis].
    Fukuyama M; Furuhata K; Oonaka K; Hara T; Sunakawa K
    Jpn J Antibiot; 2000 Jul; 53(7):522-31. PubMed ID: 11019386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical trial of T-3262 on acute enteritis. Japan Research Committee of T-3262, Research Group for Acute Infectious Enteritis].
    Aoki T; Matsubara Y; Sagara H; Tomizawa I; Takizawa Y; Nitta Y; Seo T; Kamimura M; Masuda G; Negishi M
    Kansenshogaku Zasshi; 1989 Jun; 63(6):593-605. PubMed ID: 2693541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone].
    Nomura N; Mitsuyama J; Furuta Y; Yamada H; Nakata M; Fukuda T; Yamada H; Takahata M; Minami S
    Jpn J Antibiot; 2002 Aug; 55(4):412-39. PubMed ID: 12378871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Basic and clinical studies of fleroxacin on infectious enteritis. Research Group of AM-833 on infectious enteritis].
    Sagara H; Tomizawa I; Takizawa Y; Nitta Y; Tsunoda T; Yamaguchi T; Masuda G; Negishi M; Ajisawa A; Murata M
    Kansenshogaku Zasshi; 1994 Nov; 68(11):1390-408. PubMed ID: 7829908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
    Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
    Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens.
    O'Hare MD; Felmingham D; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(4):253-7. PubMed ID: 2941257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical trial of T-3262 (Tosufloxacin tosilate) on Salmonella enteritis, and fecal drug concentration and change in the fecal microflora in the acute diarrheal patients. Japan Research Committee of T-3262, Research Group for Acute Infectious Enteritis].
    Aoki T; Matsubara Y; Sagara H; Shimizu N; Tomizawa I; Takizawa Y; Nitia Y; Seo T; Kamimura M; Kanehisa N
    Kansenshogaku Zasshi; 1989 Jul; 63(7):659-75. PubMed ID: 2693543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Nov; 48(11):1627-57. PubMed ID: 8558754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The current status of infectious enteritis in Japan--reports of the "Research Group for Infectious Enteric Diseases, Japan" in the last 5 years (1996-2000)].
    Obana M; Sagara H; Aoki T; Kim R; Takizawa Y; Tsunoda T; Irimajiri S; Yamashita K
    Kansenshogaku Zasshi; 2002 May; 76(5):355-68. PubMed ID: 12073571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological properties and expected clinical role of an injectable new quinolone antibiotic, pazufloxacin mesilate].
    Minami S; Hattori R; Matsuda A
    Nihon Yakurigaku Zasshi; 2003 Aug; 122(2):161-78. PubMed ID: 12890902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
    Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H
    Jpn J Antibiot; 1995 Nov; 48(11):1757-87. PubMed ID: 8558757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.